Background Immunotherapy represented by programmed death protein-1 (PD-1) inhibitors has gradually become the standard treatment of advanced non-small cell lung cancer (NSCLC) in recent years. changing the treatment landscape of advanced NSCLC. However. most PD-1-related studies excluded patients with NSCLC more than 70 or 75 years. https://www.foldlyers.shop/product-category/iphone-xs/